Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1676
This examiner grants 60% of resolved cases
Li N Komatsu examines cases in Art Unit 1654 of Tech Center 1600. The examiner has a total of 677 resolved cases, which is a volume for statistical analysis. The allowance rate is 59.8%, meaning that a majority of the applications reach allowance. This rate of 59.8% provides a baseline for the likelihood of success when navigating the examination process with this examiner.
The interview lift is 71.1%, which is a higher percentage than the 59.8% allowance rate. This indicates that conducting an interview is an effective strategy for advancing an application toward grant. The median days to allowance is 967. For practitioners, the combination of 677 resolved cases and a 71.1% interview lift suggests that active communication is a key component of successful prosecution within the 967-day median timeframe in Art Unit 1654.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19422266 | HYDROXYPROLINE-FREE HYDROLYZED COLLAGEN PEPTIDES AND METHODS OF MAKING AND USING THE SAME | Non-Final OA | Rochal Technologies, LLC |
| 18570390 | Rippled Antiparallel Cross-Beta Dimers and Related Materials, Compositions and Methods | Non-Final OA | The Regents of the University of California |
| 17980961 | METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS | Final Rejection | The Regents of the University of California |
| 17754712 | COMPOSITIONS AND METHODS FOR TREATING LIBERIBACTER DISEASES AND OTHER BACTERIAL DISEASES | Non-Final OA | The Regents of the University of California |
| 18258462 | Therapeutic Peptide Formulations | Final Rejection | Eli Lilly and Company |
| 18762553 | SERINE PROTEINASE INHIBITORS: SERP-1 AND SERP-1 RCL-DERIVED PEPTIDES EFFECT ON MICROBIOME COMPOSITION AND USES THEREOF | Final Rejection | Arizona Board of Regents on Behalf of Arizona State University |
| 17599211 | USE OF CYCLO(HIS-PRO) (CHP) FOR PREVENTING, AMELIORATING, OR TREATING FIBROSIS | Final Rejection | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION |
| 17184400 | FRACTURE TARGETED BONE REGENERATION THROUGH PARATHYROID HORMONE RECEPTOR STIMULATION | Non-Final OA | Purdue Research Foundation |
| 17917790 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LUNG DISEASE | Final Rejection | Arizona Board of Regents on Behalf of the University of Arizona |
| 18555169 | ERYTHROPOIETIN-DERIVED PEPTIDES FOR TREATING RELAPSING-REMITTING MULTIPLE SCLEROSIS | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 18574671 | PEPTIDE HAVING ANTICANCER ACTIVITY, AND USE THEREOF | Non-Final OA | Korea University Research and Business Foundation |
| 18004125 | THERAPEUTIC NUCLEIC ACIDS, PEPTIDES AND USES II | Non-Final OA | IMPERIAL COLLEGE INNOVATIONS LIMITED |
| 18456339 | DELTA-LIKE NON-CANONICAL NOTCH LIGAND 1 ACTIVITY MODULATORS AND USES THEREOF | Non-Final OA | Fred Hutchinson Cancer Center |
| 14004377 | PEGYLATED APELIN AND USES THEREOF | Non-Final OA | GENZYME CORPORATION |
| 18111511 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Non-Final OA | Servier Pharmaceuticals LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy